Analysis of 120 gastrectomies for appendiceal pseudomyxoma peritonei (PMP) over 20 years revealed a median survival of 104 months and a 10-year overall survival rate of 47%. While complications were observed in 32% of cases, 90-day mortality was low at 1.75%. Outcomes improved over decades, with 82.2% achieving complete cytoreduction (CCR) in the later period, […]
Category: Cytoreductive Surgery & Peritoneum
More PIPAC treatments correlate with improved patient survival
Conducting three or more pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures significantly enhances survival among patients with unresectable peritoneal surface malignancies. In a cohort of 346 patients undergoing 1200 treatments, approximately two-thirds completed at least three procedures. Disease progression was the primary reason for treatment cessation in over half of cases. The findings suggest that increasing […]
Circulating tumor cells predict poorer survival outcomes in colorectal cancer patients with peritoneal metastases
Circulating tumor cells (CTCs) detected in 37% of colorectal cancer patients with peritoneal metastases were associated with shorter recurrence-free and overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Patients with CTCs post-neoadjuvant treatment had significantly worse outcomes. Adjuvant therapy improved prognosis in CTC-positive patients but not in CTC-negative ones. CTCs may serve as a […]
Circulating Exosomal MicroRNA Panel Predicts Peritoneal Metastasis in Advanced Gastric Cancer
A circulating exosomal microRNA panel, robustly predicting peritoneal metastasis in advanced gastric cancer patients, was developed and validated with remarkable accuracy. The risk-stratification model, combined with currently used tumor markers, significantly outperformed conventional clinical factors in predicting metastasis. This novel liquid biopsy assay shows potential for improved patient selection and management, offering clinical impact in […]
CRS-HIPEC Improves Survival in Malignant Peritoneal Mesothelioma
Study of 118 patients with malignant peritoneal mesothelioma revealed cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) led to longer overall and progression-free survival. The platinum-pemetrexed combination was effective for metastatic patients and those medically inoperable. Non-surgical patients had poorer prognoses. CRS-HIPEC emerged as a safe and effective treatment, offering better survival outcomes and […]
Improved Survival with CRS + HIPEC in HCC-PM Patients
CRS + HIPEC provides significant benefits to HCC-PM patients, with 89.0% 1-year and 3-year OS rates. Some patients achieved prolonged PFS, enhancing treatment options for this challenging condition. Incorporating CRS + HIPEC into the treatment regimen is a strategic therapeutic choice for HCC-PM patients, supported by the study’s findings of extended survival outcomes. Journal Article […]
Prophylactic and Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced Colorectal Cancer
Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery shows potential in preventing peritoneal metastases in high-risk colorectal cancer. Recent randomized controlled trials, including Hipect4, demonstrate improved locoregional disease control with HIPEC, without an increase in complications. Despite negative results in trials like Prophylochip and Colopec, the methodology and patient selection criteria provide valuable insights. Ongoing […]
Effect of Surgical Treatment on Patients with Peritoneal Metastasis from Gastric Adenocarcinoma
Survival analysis of 399 patients with peritoneal metastasis from gastric adenocarcinoma revealed that surgical treatment significantly improves overall survival. Subgroup analysis suggests benefits for patients with certain tumor characteristics and previous chemotherapy. Surgery may be an option to enhance prognosis in specific groups of patients with gastric adenocarcinoma and peritoneal metastasis. Journal Article by Shen […]
Prognostic Indicators for Mucinous Appendiceal Neoplasm Patients
Identification of reliable prognostic indicators for different groups of appendiceal mucinous neoplasm patients revealed the Completeness of Cytoreduction (CC) score as a consistent predictor of survival. The Peritoneal Cancer Index (PCI) showed significance in specific subtypes, while the Prior Surgical Score (PSS) predicted outcomes in certain patient groups. Symptomatic patients or those with extensive systemic […]
Enhancing HIPEC Efficacy with Bromelain in Appendiceal Cancer
Bromelain enhances cytotoxicity and mucolytic activity in appendiceal cancer tumors, reducing mucin production and increasing drug effectiveness in heated intraperitoneal chemotherapy (HIPEC) treatments. Combined with N-acetylcysteine, bromelain significantly reduces mucin levels and boosts cell death pathways like apoptosis and autophagy. These findings suggest a promising role for bromelain as a potent pretreatment agent in augmenting […]